

VERTEX PHARMACEUTICALS INC / MA  
Form 8-K  
March 31, 2003

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): **March 31, 2003**

**Vertex Pharmaceuticals Incorporated**

(Exact name of registrant as specified in its charter)

**MASSACHUSETTS**  
(State or other jurisdiction  
of Incorporation)

**000-19319**  
(Commission  
File Number)

**04-3039129**  
(IRS Employer  
Identification No.)

**130 WAVERLY STREET  
CAMBRIDGE, MA 02139**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 444-6100**

---

---

---

**ITEM 5. OTHER EVENTS.**

On January 2, 2003, Vicki L. Sato, the Company's President, entered into a plan with Goldman, Sachs & Co., pursuant to which Goldman will undertake to sell, subject to a limit order, an aggregate of 200,000 shares of the Company's stock issuable upon exercise of options held by Dr. Sato. Sales under the plan are to begin no earlier than 90 days after adoption of the plan, and will take place at specified intervals between April 2, 2003 and March 31, 2004.

---

**SIGNATURES**

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED  
(Registrant)

Date: March 31, 2003

By: /s/ IAN F. SMITH

---

Ian F. Smith  
*Vice President and Chief Financial Officer*

---

QuickLinks

SIGNATURES